Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

NCT00722176 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: BL-1020
DRUG: BL-1020 10-30 mg
DRUG: risperidone

Sponsor

BioLineRx, Ltd.